Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) plus leuprolide (combo): EMBARK post hoc analysis.

Detalles Bibliográficos
Publicado en:Journal of Clinical Oncology Vol. 43; pp. 159 - 447
Autores principales: Freedland, Stephen J., Gleave, Martin, De Giorgi, Ugo, Rannikko, Antti, Sridharan, Swetha, Brasso, Klaus, Woo, Henry H., Gómez Caamaño, Antonio, Nordquist, Luke, Tang, Yiyun, Croitoru, Ruslan, Rosales, Matt, Kalac, Matko, Peraud, Olivier, Wang, Fong, Shore, Neal D.
Formato: Journal Article
Publicado: American Society of Clinical Oncology 2/10/2025 Supplement5
Acceso en línea:Ver este registro en EBSCOhost